Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis

The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna's KYSA-6 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EM... Biopharmaceuticals, FDA Kyverna Therapeutics, chimeric antigen receptor, Myasthenia Gravis, autoimmune
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news